J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published as JGV in Press, 10.1099/vir.0.010199-0 on May 7, 2009 J Gen Virol 90 (2009), 1806-1811; DOI 10.1099/vir.0.010199-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
vir.0.010199-0v1
90/8/1806    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Suemori, K.
Right arrow Articles by Yasukawa, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suemori, K.
Right arrow Articles by Yasukawa, M.
Agricola
Right arrow Articles by Suemori, K.
Right arrow Articles by Yasukawa, M.

Short Communication

HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes

Koichiro Suemori1, Hiroshi Fujiwara1, Toshiki Ochi1, Taiji Ogawa1, Masao Matsuoka2, Tadashi Matsumoto3, Jean-Michel Mesnard4 and Masaki Yasukawa1

1 Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
2 Laboratory for Virus Immunology, Institute for Virus Research, Kyoto University, Kyoto, Japan
3 Division of Hematology and Oncology, Jiaikai Imamura Hospital, Kagoshima, Japan
4 Université Montpellier 1, Centre d'Études d'Agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS UM5236, Montpellier, France

Correspondence
Masaki Yasukawa
yasukawa{at}m.ehime-u.ac.jp

Recently, HBZ has been reported to play an important role in the proliferation of adult T-cell leukaemia (ATL) cells and might be a target of novel therapy for ATL. To develop a novel immunotherapy for ATL, we verified the feasibility of cellular immunotherapy targeting HBZ. We established an HBZ-specific and HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) clone. Detailed study using this CTL clone clearly showed that HBZ is certainly an immunogenic protein recognizable by human CTLs; however, HBZ-specific CTLs could not lyse ATL cells. Failure of HBZ-specific CTLs to recognize human T-cell leukemia virus type 1 (HTLV-1)-infected cells might be due to a low level of HBZ protein expression in ATL cells and resistance of HTLV-1-infected cells to CTL-mediated cytotoxicity. Although HBZ plays an important role in the proliferation of HTLV-1-infected cells, it may also provide a novel mechanism that allows them to evade immune recognition.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2009 by the Society for General Microbiology.